NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Taipei Veterans General Hospital, Taiwan
Conditions: Fabry Disease, Cardiac Variant
Interventions: Family pedigree and data collection
Fabry disease is caused by the deficiency or absence of alpha-galactosidase A (α-Gal A) activity, leading to progressive deposition of glycosphingolipids, mainly globotriaosylceramide (Gb3), in the lysosomes of multiple tissues and organs. In Taiwan, Dr. Niu first revealed a surprisingly high incidence (approximately one in 1,600 males) of a cardiac variant GLA splicing mutation, IVS4+919G\>A, in newborn screening. Patients who carried the IVS4 + 919G \> A mutation and were older than 40 years had a higher prevalence of hypertrophic cardiomyopathy. Endocardial biopsy of these patients with hypertrophic cardiomyopathy showed significant Gb3 accumulation in the cardiomyocytes. Although the hotspot IVS4+919G\>A mutation is now being observed with greater frequency, understanding of the natural course of cardiac variant Fabry disease with this specific mutation remains limited. Therefore, our study would like to conduct a study to approach the natural history among patients with Chinese hotspot late-onset Fabry mutation IVS4+919G\>A through family pedigree analysis.
Sex: ALL
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Fabry IVS4 female newborn family members. * Patients and/or their legal representatives who are willing to provide written informed consent Exclusion Criteria: * No blood relatives to the IVS4 female newborn family